Literature DB >> 22674572

Fluorodeoxyglucose positron emission tomography in semantic dementia after 6 months of memantine: an open-label pilot study.

Tiffany W Chow1, David Fam, Ariel Graff-Guerrero, Nicolaas P G Verhoeff, David F Tang-Wai, Mario Masellis, Sandra E Black, Alan A Wilson, Sylvain Houle, Bruce G Pollock.   

Abstract

OBJECTIVES: To follow up on the increases we reported in normalized metabolic activity in salience network hubs from a 2-month open-label study of memantine in frontotemporal dementia (FTD).
METHODS: We repeated fluorodeoxyglucose positron emission tomography (FDG-PET) after 6 months of drug use and subjected the data to Statistical Parametrical Mapping (SPM) analysis to reveal clusters of significant change from baseline. We also sought correlations between changes in behavioral disturbances on the Frontal Behavioral Inventory (FBI) and the PET signal.
RESULTS: Recruitment of one progressive nonfluent aphasia and one behavioral variant FTD precluded statistical analysis for any FTD subtype other than semantic dementia (SD). The baseline-to-6-month interval showed increased normalized metabolic activity in the left orbitofrontal cortex (p < 0.002) for five participants with SD. The 2-6-month interval revealed a late increase in normalized metabolic activity in the left insula (p < 0.013), right insula (p < 0.009), and left anterior cingulate (p < 0.005). The right anterior cingulate showed both an initial increase and a delayed further increase (2-6 months, p < 0.016). FBI scores worsened by 43.3%. One participant with SD opted not to continue memantine beyond 2 months yet showed similar FDG-PET increases.
CONCLUSIONS: Increases in normalized cortical metabolic activity in salience network hubs were sustained in SD over a 6-month period. Because one participant without medication also showed these changes, further investigation is recommended through a double-blind, placebo-controlled study with FDG-PET as an outcome measure.
Copyright © 2012 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22674572      PMCID: PMC3467357          DOI: 10.1002/gps.3832

Source DB:  PubMed          Journal:  Int J Geriatr Psychiatry        ISSN: 0885-6230            Impact factor:   3.485


  14 in total

1.  Predominant ventromedial frontopolar metabolic impairment in frontotemporal dementia.

Authors:  Eric Salmon; Gaëtan Garraux; Xavier Delbeuck; Fabienne Collette; Elke Kalbe; Gerhard Zuendorf; Daniela Perani; Ferruccio Fazio; Karl Herholz
Journal:  Neuroimage       Date:  2003-09       Impact factor: 6.556

Review 2.  Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria.

Authors:  D Neary; J S Snowden; L Gustafson; U Passant; D Stuss; S Black; M Freedman; A Kertesz; P H Robert; M Albert; K Boone; B L Miller; J Cummings; D F Benson
Journal:  Neurology       Date:  1998-12       Impact factor: 9.910

3.  Memantine in moderate-to-severe Alzheimer's disease.

Authors:  Barry Reisberg; Rachelle Doody; Albrecht Stöffler; Frederick Schmitt; Steven Ferris; Hans Jörg Möbius
Journal:  N Engl J Med       Date:  2003-04-03       Impact factor: 91.245

4.  Specificity of changes in cerebral blood flow in patients with frontal lobe dementia.

Authors:  S E Starkstein; R Migliorelli; A Tesón; L Sabe; S Vázquez; M Turjanski; R G Robinson; R Leiguarda
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-07       Impact factor: 10.154

5.  Effect of memantine treatment on regional cortical metabolism in Alzheimer's disease.

Authors:  David L Sultzer; Rebecca J Melrose; Dylan G Harwood; Olivia Campa; Mark A Mandelkern
Journal:  Am J Geriatr Psychiatry       Date:  2010-07       Impact factor: 4.105

6.  Memantine in behavioral variant frontotemporal dementia: negative results.

Authors:  Martine Vercelletto; Claire Boutoleau-Bretonnière; Christelle Volteau; Michèle Puel; Sophie Auriacombe; Marie Sarazin; Bernard-François Michel; Philippe Couratier; Catherine Thomas-Antérion; Patrice Verpillat; Audrey Gabelle; Véronique Golfier; Evelyne Cerato; Lucette Lacomblez
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

7.  Decomposition of metabolic brain clusters in the frontal variant of frontotemporal dementia.

Authors:  Eric Salmon; Nacer Kerrouche; Karl Herholz; Daniela Perani; Vjera Holthoff; Bettina Beuthien-Baumann; Christian Degueldre; Christian Lemaire; André Luxen; Jean-Claude Baron; Fabienne Collette; Gaëtan Garraux
Journal:  Neuroimage       Date:  2005-12-15       Impact factor: 6.556

8.  Divergent network connectivity changes in behavioural variant frontotemporal dementia and Alzheimer's disease.

Authors:  Juan Zhou; Michael D Greicius; Efstathios D Gennatas; Matthew E Growdon; Jung Y Jang; Gil D Rabinovici; Joel H Kramer; Michael Weiner; Bruce L Miller; William W Seeley
Journal:  Brain       Date:  2010-04-21       Impact factor: 13.501

9.  Brain metabolic and clinical effects of rivastigmine in Alzheimer's disease.

Authors:  S G Potkin; R Anand; K Fleming; G Alva; D Keator; D Carreon; J Messina; J C Wu; R Hartman; J H Fallon
Journal:  Int J Neuropsychopharmacol       Date:  2001-09       Impact factor: 5.176

10.  Open-label study of the short-term effects of memantine on FDG-PET in frontotemporal dementia.

Authors:  Tiffany W Chow; Ariel Graff-Guerrero; Nicolaas Plg Verhoeff; Malcolm A Binns; David F Tang-Wai; Morris Freedman; Mario Masellis; Sandra E Black; Alan A Wilson; Sylvain Houle; Bruce G Pollock
Journal:  Neuropsychiatr Dis Treat       Date:  2011-07-13       Impact factor: 2.570

View more
  3 in total

1.  Efficacy of memantine on neuropsychiatric symptoms associated with the severity of behavioral variant frontotemporal dementia: A six-month, open-label, self-controlled clinical trial.

Authors:  Pan Li; Wei Quan; Yu-Ying Zhou; Yan Wang; Hui-Hong Zhang; Shuai Liu
Journal:  Exp Ther Med       Date:  2016-04-20       Impact factor: 2.447

Review 2.  The emerging role of PET imaging in dementia.

Authors:  Leonardo Iaccarino; Arianna Sala; Silvia Paola Caminiti; Daniela Perani
Journal:  F1000Res       Date:  2017-10-12

Review 3.  Alzheimer's Dementia: The Emerging Role of Positron Emission Tomography.

Authors:  Shailendra Mohan Tripathi; Alison D Murray
Journal:  Neuroscientist       Date:  2021-03-04       Impact factor: 7.235

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.